LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

30.3 0.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.89

Max

31.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-30M -30M
Verkoop	-26M 77M
Winstmarge	-38.823
Werknemers	524
EBITDA	-12M -8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+119.74% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-214M 1.4B
Vorige openingsprijs	30.27
Vorige sluitingsprijs	30.3

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 23:58 UTC

Winsten

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mei 2026, 22:57 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mei 2026, 23:52 UTC

Winsten

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mei 2026, 23:28 UTC

Marktinformatie

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mei 2026, 23:11 UTC

Winsten

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mei 2026, 23:06 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mei 2026, 23:05 UTC

Winsten

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mei 2026, 23:04 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mei 2026, 23:02 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mei 2026, 23:00 UTC

Marktinformatie

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 mei 2026, 22:45 UTC

Marktinformatie

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mei 2026, 22:42 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mei 2026, 22:33 UTC

Winsten

Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mei 2026, 22:32 UTC

Winsten

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mei 2026, 22:31 UTC

Winsten

Macquarie: 68% of FY Income From International >MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mei 2026, 22:30 UTC

Winsten

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mei 2026, 22:29 UTC

Winsten

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mei 2026, 22:27 UTC

Winsten

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mei 2026, 22:26 UTC

Winsten

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mei 2026, 22:25 UTC

Winsten

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

119.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.67 USD 119.74%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.